Federated Hermes’s Harvard Bioscience HBIO Stock Holding History

Federated Hermes’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$356	Sell	73 -93	-56%	-$520	﹤0.01%	2035
2025 Q4	$1.11K	Hold	166	–	–	﹤0.01%	2013
2025 Q3	$726	Hold	166	–	–	﹤0.01%	2088
2025 Q2	$735	Hold	166	–	–	﹤0.01%	2018
2025 Q1	$937	Buy	+166	New	+$2.13K	﹤0.01%	2002
2022 Q1	–	Sell	-85	Closed	-$6K	–	2240
2021 Q4	$6K	Hold	85	–	–	﹤0.01%	1979
2021 Q3	$6K	Hold	85	–	–	﹤0.01%	2027
2021 Q2	$7K	Buy	85 +25	+42%	+$1.77K	﹤0.01%	2009
2021 Q1	$3K	Buy	+60	New	+$2.92K	﹤0.01%	2093
2015 Q2	–	Sell	-35	Closed	-$2K	–	1999
2015 Q1	$2K	Sell	35 -147	-81%	-$7.9K	﹤0.01%	1941
2014 Q4	$10K	Buy	182 +12	+7%	+$572	﹤0.01%	1745
2014 Q3	$7K	Buy	+170	New	+$7.82K	﹤0.01%	1782

Other funds holding HBIO

WCM

Weber Capital Management San Francisco, California $100M AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CCM

Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes's HBIO Position: Q1 2026 in Review

Federated Hermes reduced its Harvard Bioscience (HBIO) stake by 56% in Q1 2026, selling an estimated $520 and leaving 73 shares worth $356. The position accounts for ﹤0.01% of the portfolio, ranked #2035.

Federated Hermes first reported a position in HBIO in Q3 2014 and has held it in 12 quarters since. The position peaked at $10K in Q4 2014. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

Federated Hermes held 73 shares of Harvard Bioscience worth $356 as of Q1 2026.
Federated Hermes sold 93 Harvard Bioscience shares in Q1 2026, an estimated $520.
Harvard Bioscience made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #2035 holding.
Federated Hermes first reported a position in Harvard Bioscience in Q3 2014 and has held it in 12 quarters since.
Federated Hermes's Harvard Bioscience position peaked at $10K in Q4 2014.
36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.